Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 36
Filtrar
1.
J Integr Neurosci ; 21(1): 35, 2022 Jan 28.
Artigo em Inglês | MEDLINE | ID: mdl-35164471

RESUMO

Owing to the small number of patients with tyrosine hydroxylase (TH) deficiency, no genotype-phenotype correlations have yet been identified. To investigate the genotype-phenotype correlation of R233H mutation in TH deficiency, we analyzed the clinical manifestations and treatment responses of four patients with the R233H homozygous mutation. Thirty-eight additional patients, available from the literature, known to be homozygous or heterozygous for the R233H mutation, were combined with the four cases from our hospital. Data for a total of 42 patients were retrieved. Our four patients showed clinical presentation consistent with Type A TH deficiency, and responded well to levodopa therapy, with an improvement in clinical symptoms within 1-2 weeks. In the 42 patients, 20 of 42 patients (48%) were homozygous and 22 (52%) were heterozygous for the R233H mutation. Of the 20 patients who were homozygous for the R233H mutation, a majority (80%) suffered from Type A TH deficiency. Of the 8 patients that were heterozygous for the R233H/the mutation located downstream of exon 11, 7 patients (86%) suffered from Type B TH deficiency. Of the 7 patients who were heterozygous for the R233H/nonsense mutation, 6 (86%) suffered from Type B TH deficiency. Genotype-phenotype correlation of R233H mutation was observed in TH deficiency. The homozygous R233H mutation frequently manifests as Type A TH deficiency, whereas R233H/nonsense mutation or any mutation located downstream of exon 11 manifests as Type B TH deficiency.


Assuntos
Distúrbios Distônicos/congênito , Criança , Pré-Escolar , Distúrbios Distônicos/genética , Distúrbios Distônicos/fisiopatologia , Feminino , Estudos de Associação Genética , Humanos , Lactente , Masculino , Fenótipo
2.
Parkinsonism Relat Disord ; 93: 111-113, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34920839

RESUMO

Tyrosine hydroxylase (TH) deficiency is an autosomal recessive condition first described as a progressive, early-onset hypokinetic-rigid and dystonic syndrome that was responsive to levodopa. Here we present a child with developmental regression, proximal tremor, and encephalopathy found to have tyrosine hydroxylase deficiency in whom treatment resulted in acquisition of developmental milestones.


Assuntos
Encefalopatias/tratamento farmacológico , Deficiências do Desenvolvimento/tratamento farmacológico , Distúrbios Distônicos/congênito , Tremor/tratamento farmacológico , Encefalopatias/congênito , Deficiências do Desenvolvimento/genética , Distúrbios Distônicos/complicações , Distúrbios Distônicos/tratamento farmacológico , Humanos , Lactente , Levodopa/uso terapêutico , Masculino , Resultado do Tratamento , Tremor/congênito
4.
Gut Microbes ; 13(1): 1866974, 2021 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-33459114

RESUMO

Parkinson's disease (PD) is a common neurodegenerative disorder characterized primarily by motor and non-motor gastrointestinal (GI) deficits. GI symptoms' including compromised intestinal barrier function often accompanies altered gut microbiota composition and motor deficits in PD. Therefore, in this study, we set to investigate the role of gut microbiota and epithelial barrier dysfunction on motor symptom generation using a rotenone-induced mouse model of PD. We found that while six weeks of 10 mg/kg of chronic rotenone administration by oral gavage resulted in loss of tyrosine hydroxylase (TH) neurons in both germ-free (GF) and conventionally raised (CR) mice, the decrease in motor strength and coordination was observed only in CR mice. Chronic rotenone treatment did not disrupt intestinal permeability in GF mice but resulted in a significant change in gut microbiota composition and an increase in intestinal permeability in CR mice. These results highlight the potential role of gut microbiota in regulating barrier dysfunction and motor deficits in PD.


Assuntos
Gastroenteropatias/patologia , Microbioma Gastrointestinal/fisiologia , Trato Gastrointestinal/microbiologia , Doença de Parkinson/patologia , Rotenona/toxicidade , Junções Íntimas/patologia , Animais , Eixo Encéfalo-Intestino , Modelos Animais de Doenças , Disbiose/microbiologia , Distúrbios Distônicos/congênito , Distúrbios Distônicos/patologia , Feminino , Vida Livre de Germes/fisiologia , Masculino , Camundongos , Junções Íntimas/efeitos dos fármacos , Tirosina 3-Mono-Oxigenase/metabolismo
5.
Biochimie ; 183: 126-132, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33309753

RESUMO

Tyrosine hydroxylase (TH) catalyses the (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)-dependent conversion of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-Dopa), which is the rate-limiting step in the synthesis of dopamine and other catecholamine neurotransmitters and hormones. Dysfunctional mutant TH causes tyrosine hydroxylase deficiency (THD), characterized by symptoms ranging from mild l-Dopa responsive dystonia to severe neuropathy. THD-associated mutations often present misfolding and a propensity to aggregate, characteristics that can also be manifested by dysregulated wild-type TH. TH - and subsequently dopamine - is also reduced in Parkinson's disease (PD) due to the selective death of dopaminergic neurons. Thus, TH is a target for stabilizing small molecular weight compounds that can function as pharmacological chaperones, restoring enzyme folding and function. In this work we carried out a screening of a compound library with 1280 approved drugs and we identified levalbuterol, a beta2-adrenergic agonist that is broadly used in asthma treatment, as an interesting validated binder of human TH. Levalbuterol stabilized TH with reduced affinity compared to dopamine, the end-product and regulatory feedback inhibitor of TH, but without compromising enzymatic activity. Moreover, levalbuterol also delays the formation of TH aggregates and makes the enzyme less sensitive to dopamine, effects that could contribute to ameliorate disorders related to TH, such as THD and PD.


Assuntos
Dopamina/química , Levalbuterol/química , Agregados Proteicos , Dobramento de Proteína , Tirosina 3-Mono-Oxigenase/química , Distúrbios Distônicos/congênito , Distúrbios Distônicos/enzimologia , Distúrbios Distônicos/genética , Humanos , Tirosina 3-Mono-Oxigenase/genética
6.
Medicine (Baltimore) ; 99(33): e21753, 2020 Aug 14.
Artigo em Inglês | MEDLINE | ID: mdl-32872068

RESUMO

RATIONAL: Tyrosine hydroxylase deficiency (THD) is a rare cause of dopa-responsive dystonia (DRD). Although the symptoms of DRD may be improved by treatment with L-dopa, the low morbidity of THD can lead to its misdiagnosis. Thus, it is important for physicians to be aware of THD as a cause of DRD. PATIENT CONCERNS: We report 3 cases of THD. A 5-year-old boy with DRD was diagnosed with THD and found to have compound heterozygous mutations of the TH gene, including TH:c.647G>C from his mother and TH:c.646G>A from his father. Two female siblings also were found to have TH:c.698G>A from their mother and TH:c.710T>C from their father. The younger daughter, at age 3.5 years, was diagnosed with DRD caused by THD, and then the diagnosis of the older daughter, at age 11 years, was changed from cerebral palsy to DRD caused by THD. DIAGNOSIS: The diagnosis of dopa-responsive dystonia caused by tyrosine hydroxylase deficiency was determined by whole exome sequencing. INTERVENTION: They all treated with low dose levodopa and benserazide tablets. OUTCOMES: The boy had a very good therapeutic effect, and he could walk very well by the second day of treatment. The younger sister of the siblings had a partial therapeutic effect, but her elder sister was only little effective with a milder improvement of dystonia and improvement of myodynamia. CONCLUSION: The characteristics of THD are heterogeneous, and its phenotypes are classified as type A or type B according to increasing severity. Generally, L-dopa has a good therapeutic effect in cases with type A phenotypes. We reviewed 87 cases of reported in the literature and found that c.698G>A and c.707T>C are hot spot mutations. Changes on cerebral magnetic resonance imaging were nonspecific. Analysis of neurotransmitter levels in cerebrospinal fluid is an invasive means of achieving a biochemical diagnosis.


Assuntos
Distúrbios Distônicos/congênito , Tirosina 3-Mono-Oxigenase/genética , Benserazida/uso terapêutico , Criança , Pré-Escolar , Dopaminérgicos/uso terapêutico , Distúrbios Distônicos/complicações , Distúrbios Distônicos/tratamento farmacológico , Distúrbios Distônicos/genética , Humanos , Levodopa/uso terapêutico , Masculino
7.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi ; 37(4): 455-458, 2020 Apr 10.
Artigo em Chinês | MEDLINE | ID: mdl-32219836

RESUMO

OBJECTIVE: To explore the clinical characteristics and genetic variants in a child with tyrosine hydroxylase-deficient infantile Parkinsonism with motor delay. METHODS: Clinical feature of the patient was summarized. Genomic DNA was extracted from peripheral blood samples taken from the child and her family members. All exons of GCH1, TH and SPR genes were subjected to targeted capture and next-generation sequencing. Suspected variants were verified by Sanger sequencing. RESULTS: The child could not sit alone at 7 month and 11 days. Physical examination suggested motor retardation and hypotonia, limb stiffness, head nodding, slight torticollis, and language and intellectual developmental delays. She developed involuntary shaking of limbs at 3 month old, which lasted approximately 10 seconds and aggregated with excitement and before sleeping. Cranial MRI revealed widening of subarachnoid space on the temporomandibular and particularly temporal sides. Genetic testing revealed that she has carried a nonsense c.457C>T (p.R153X) variant, which was known to be pathogenic, and a novel missense c.720C>G (p.I240M) variant of the TH gene. The two variants were derived from her father and mother, respectively. CONCLUSION: The child was diagnosed as tyrosine hydroxylase-deficient infantile Parkinsonism with motor delay due to compound heterozygous variants of the TH gene. Above finding has enriched the spectrum of TH gene variants.


Assuntos
Distúrbios Distônicos/congênito , Transtornos Parkinsonianos/genética , Tirosina 3-Mono-Oxigenase/genética , Encéfalo/diagnóstico por imagem , Códon sem Sentido , Distúrbios Distônicos/genética , Feminino , Testes Genéticos , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Lactente , Imageamento por Ressonância Magnética , Mutação
8.
Int J Dev Neurosci ; 78: 28-32, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31419477

RESUMO

Tyrosine hydroxylase (TH) deficiency is a rare autosomal recessive inborn error of dopamine transmission, which the deficient gene is at the chromosome 11, also called'Segawa Syndrome'. TH converts tyrosine into L-DOPA, which is the direct precursor of catecholamine biosynthesis. TH deficiency causes a neurological disease with primary extrapyramidal signs and a variable response to L-DOPA. We report three patients in China who were diagnosed with Tyrosine hydroxylase (TH) deficiency by genetic testing and clinical manifestations. After L-DOPA treatment, their condition had sustained improvement.


Assuntos
Dopaminérgicos/uso terapêutico , Distúrbios Distônicos/congênito , Levodopa/uso terapêutico , China , Distúrbios Distônicos/tratamento farmacológico , Feminino , Humanos , Lactente , Masculino , Resultado do Tratamento
9.
Neurobiol Aging ; 73: 231.e1-231.e6, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30314816

RESUMO

GCH1 encodes the enzyme guanosine triphospahte (GTP) cyclohydrolase 1, essential for dopamine synthesis in nigrostriatal cells, and rare mutations in GCH1 may lead to Dopa-responsive dystonia (DRD). While GCH1 is implicated in genomewide association studies in Parkinson's disease (PD), only a few studies examined the role of rare GCH1 variants in PD, with conflicting results. In the present study, GCH1 and its 5' and 3' untranslated regions were sequenced in 1113 patients with PD and 1111 controls. To examine the association of rare GCH1 variants with PD, burden analysis was performed. Three rare GCH1 variants, which were previously reported to be pathogenic in DRD, were found in five patients with PD and not in controls (sequence Kernel association test, p = 0.024). A common haplotype, tagged by rs841, was associated with a reduced risk for PD (OR = 0.71, 95% CI = 0.61-0.83, p = 1.24 × 10-4), and with increased GCH1 expression in brain regions relevant for PD (www.gtexportal.org). Our results support a role for rare, DRD-related variants, and common GCH1 variants in the pathogenesis of PD.


Assuntos
GTP Cicloidrolase/genética , Estudos de Associação Genética , Variação Genética/genética , Doença de Parkinson/genética , Adulto , Idoso , Encéfalo/metabolismo , Distúrbios Distônicos/congênito , Distúrbios Distônicos/genética , Feminino , GTP Cicloidrolase/metabolismo , Expressão Gênica , Humanos , Masculino , Pessoa de Meia-Idade , Fenilcetonúrias/genética
10.
Medicine (Baltimore) ; 97(44): e12870, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30383639

RESUMO

RATIONALE: Autosomal-recessive dopa-responsive dystonia (DRD) is a rare clinical disorder presenting as bradykinesia, dystonia, tremor and even severe encephalopathy, and caused by tyrosine hydroxylase deficiency (THD). We report a case of compound heterozygous mutations in the TH gene in a Chinese family with autosomal-recessive DRD herein. PATIENT CONCERNS: A 16-month-old Chinese boy presented with symptoms of movement disorder and growth retardation in his infant period. DIAGNOSES: The genetic test revealed compound heterozygous mutations in the TH gene at c.457C>T and c.698G>A, which are pathogenic of DRD. INTERVENTIONS: The patient was administrated low-dose levodopa. OUTCOMES: The treatment resulted in the substantial improvement of dystonia. His long-term neurological outcome need follow-up for years. LESSONS: Gene mutation analysis is helpful and necessary to diagnose DRD and has important guiding significance for the subsequent treatment.


Assuntos
Distúrbios Distônicos/congênito , Levodopa/uso terapêutico , Tirosina 3-Mono-Oxigenase/genética , Povo Asiático/genética , Distúrbios Distônicos/tratamento farmacológico , Distúrbios Distônicos/genética , Testes Genéticos , Heterozigoto , Humanos , Lactente , Masculino , Mutação
11.
Nat Rev Dis Primers ; 4(1): 25, 2018 09 20.
Artigo em Inglês | MEDLINE | ID: mdl-30237473

RESUMO

Dystonia is a neurological condition characterized by abnormal involuntary movements or postures owing to sustained or intermittent muscle contractions. Dystonia can be the manifesting neurological sign of many disorders, either in isolation (isolated dystonia) or with additional signs (combined dystonia). The main focus of this Primer is forms of isolated dystonia of idiopathic or genetic aetiology. These disorders differ in manifestations and severity but can affect all age groups and lead to substantial disability and impaired quality of life. The discovery of genes underlying the mendelian forms of isolated or combined dystonia has led to a better understanding of its pathophysiology. In some of the most common genetic dystonias, such as those caused by TOR1A, THAP1, GCH1 and KMT2B mutations, and idiopathic dystonia, these mechanisms include abnormalities in transcriptional regulation, striatal dopaminergic signalling and synaptic plasticity and a loss of inhibition at neuronal circuits. The diagnosis of dystonia is largely based on clinical signs, and the diagnosis and aetiological definition of this disorder remain a challenge. Effective symptomatic treatments with pharmacological therapy (anticholinergics), intramuscular botulinum toxin injection and deep brain stimulation are available; however, future research will hopefully lead to reliable biomarkers, better treatments and cure of this disorder.


Assuntos
Distonia/diagnóstico , Distonia/tratamento farmacológico , Baclofeno/uso terapêutico , Gânglios da Base/anatomia & histologia , Gânglios da Base/fisiopatologia , Toxinas Botulínicas Tipo A/uso terapêutico , Dopaminérgicos , Distonia/classificação , Distúrbios Distônicos/congênito , Distúrbios Distônicos/diagnóstico , Distúrbios Distônicos/genética , Agonistas dos Receptores de GABA-B/uso terapêutico , GTP Cicloidrolase/genética , Humanos , Levodopa/uso terapêutico , Fármacos Neuromusculares/uso terapêutico , Qualidade de Vida
12.
Neurobiol Aging ; 68: 159.e3-159.e6, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29724574

RESUMO

Whole-exome sequencing of Parkinson's disease (PD) patients has revealed that the frequency of GTP-cyclohydrolase I (GCH1) variants was significantly higher in patients than in controls. GCH1 rs11158026 was also found to increase the risk of PD. To investigate genetic contribution of dopa-responsive dystonia-related genes to PD, GCH1, and tyrosine hydroxylase (TH) were tested in PD patients. A total of 859 study subjects comprising 421 patients with PD and 438 controls were recruited. For GCH1 gene, one known variant (c.239G > A, p.S80N) was detected in a patient who was diagnosed with PD clinically. In TH, 3 heterozygous variants, c.1495G > A (p. V499M, rs1800033), c.334 A > G (p.V112M, rs6356), and c.813 G > A (p. K271K, rs6357), were identified. After stratification by age, the frequency of rs6356G allele was significantly lower (p = 0.041) for the late-onset PD group than controls. Our results indicate that to analyze the relationship between dopa-responsive dystonia-related genes and PD, it is important to screen GCH1 and test rs6356 of TH in a larger sample.


Assuntos
GTP Cicloidrolase/genética , Estudos de Associação Genética , Predisposição Genética para Doença/genética , Variação Genética/genética , Doença de Parkinson/genética , Tirosina 3-Mono-Oxigenase/genética , Povo Asiático/genética , Distúrbios Distônicos/congênito , Distúrbios Distônicos/genética , Frequência do Gene/genética , Humanos
13.
Indian Pediatr ; 54(6): 499-501, 2017 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-28667724

RESUMO

BACKGROUND: Tyrosine Hydroxylase deficiency is a rare neurotransmitter disorder. CASE CHARACTERISTICS: An Indian family with the disorder. OBSERVATIONS: Phenotypic variation, elevated serum prolactin, genetic confirmation, and partial treatment-responsiveness. MESSAGE: Tyrosine Hydroxylase deficiency is a treatable inborn error of metabolism and serum prolactin assists in diagnosis.


Assuntos
Distúrbios Distônicos/congênito , Dopaminérgicos/uso terapêutico , Feminino , Humanos , Índia , Lactente , Levodopa/uso terapêutico , Masculino , Tirosina 3-Mono-Oxigenase/genética
14.
Biochim Biophys Acta Mol Basis Dis ; 1863(6): 1171-1182, 2017 06.
Artigo em Inglês | MEDLINE | ID: mdl-28366877

RESUMO

Upstream open reading frames (uORFs) have emerged as major post-transcriptional regulatory elements in eukaryotic species. In general, uORFs are initiated by a translation start codon within the 5' untranslated region of a gene (upstream ATG; uATG), and they are negatively correlated with translational efficiency. In addition to their translational regulatory role, some uORFs can code for biologically active short peptides. The importance of uATGs/uORFs is further underscored by human diseases associated with single nucleotide polymorphisms (SNPs), which disrupt existing uORFs or introduce novel uORFs. Although several functional proteins translated from naturally occurring uORFs have been described, the coding potential of uORFs created by SNPs has been ignored because of the a priori assumption that these proteins are short-lived with no likely impact on protein homeostasis. Thus, studies on SNP-created uORFs are limited to their translational effects, leaving unexplored the potential cellular consequences of a SNP/uORF-encoded protein. Here, we investigate functionality of a uATG/uORF introduced by a +142C>T SNP within the GCH1 gene and associated with a familial form of DOPA Responsive Dystonia. We report that the +142C>T SNP represses GCH1 translation, and introduces a short, frame shifted uORF that encodes a 73-amino acid peptide. This peptide is localized within the nucleus and compromises cell viability upon proteasome inhibition. Our work extends the list of uATG/uORF associated diseases and advances research on peptides translated from SNP-introduced uORFs, a neglected component of the proteome.


Assuntos
Códon , GTP Cicloidrolase , Fases de Leitura Aberta , Polimorfismo de Nucleotídeo Único , Biossíntese de Proteínas , Linhagem Celular Tumoral , Distúrbios Distônicos/congênito , Distúrbios Distônicos/genética , Distúrbios Distônicos/metabolismo , Distúrbios Distônicos/patologia , GTP Cicloidrolase/biossíntese , GTP Cicloidrolase/genética , Células HEK293 , Humanos
17.
Stem Cell Res ; 17(3): 580-583, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27934587

RESUMO

Fibroblasts from a male patient with compound heterozygous variants in the tyrosine hydroxylase gene (TH; OMIM: 191290; c.[385-C>T]; [692-G>C]/p.[R129*]; [R231P]), the rate-limiting enzyme for dopamine synthesis, were reprogrammed to iPSCs using episomal reprogramming delivering the reprogramming factors Oct3/4, Sox2, L-Myc, Lin28, Klf4 and p53 shRNA Okita et al. (2011). Pluripotency of TH-1 iPSC was verified by immunohistochemistry and RT-PCR analysis. Cells exhibited a normal karyotype and differentiated spontaneously into the 3 germ layers in vitro. TH-1 iPSC represents the first model system to study the pathomechanism of this rare metabolic disease and provides a useful tool for drug testing.


Assuntos
Distúrbios Distônicos/congênito , Células-Tronco Pluripotentes Induzidas/citologia , Tirosina 3-Mono-Oxigenase/genética , Sequência de Bases , Diferenciação Celular , Linhagem Celular , Reprogramação Celular , DNA/química , DNA/isolamento & purificação , DNA/metabolismo , Distúrbios Distônicos/genética , Distúrbios Distônicos/patologia , Corpos Embrioides/citologia , Corpos Embrioides/metabolismo , Fibroblastos/citologia , Heterozigoto , Humanos , Células-Tronco Pluripotentes Induzidas/metabolismo , Cariótipo , Fator 4 Semelhante a Kruppel , Masculino , Plasmídeos/genética , Plasmídeos/metabolismo , Polimorfismo de Nucleotídeo Único , Interferência de RNA , Análise de Sequência de DNA , Fatores de Transcrição/genética , Fatores de Transcrição/metabolismo , Proteína Supressora de Tumor p53/antagonistas & inibidores , Proteína Supressora de Tumor p53/genética , Proteína Supressora de Tumor p53/metabolismo
18.
PLoS One ; 11(10): e0164589, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27736960

RESUMO

Model-based optimization approaches are valuable in developing new drugs for human metabolic disorders. The core objective in most optimal drug designs is positive therapeutic effects. In this study, we considered the effects of therapeutic, adverse, and target variation simultaneously. A fuzzy optimization method was applied to formulate a multiobjective drug design problem for detecting enzyme targets in the presynaptic dopamine metabolic network to remedy two types of enzymopathies caused by deficiencies of vesicular monoamine transporter 2 (VMAT2) and tyrosine hydroxylase (TH). The fuzzy membership approach transforms a two-stage drug discovery problem into a unified decision-making problem. We developed a nested hybrid differential evolution algorithm to efficiently identify a set of potential drug targets. Furthermore, we also simulated the effects of current clinical drugs for Parkinson's disease (PD) in this model and tried to clarify the possible causes of neurotoxic and neuroprotective effects. The optimal drug design could yield 100% satisfaction grade when both therapeutic effect and the number of targets were considered in the objective. This scenario required regulating one to three and one or two enzyme targets for 50%-95% and 50%-100% VMAT2 and TH deficiencies, respectively. However, their corresponding adverse and target variation effect grades were less satisfactory. For the most severe deficiencies of VMAT2 and TH, a compromise design could be obtained when the effects of therapeutic, adverse, and target variation were simultaneously applied to the optimal drug discovery problem. Such a trade-off design followed the no free lunch theorem for optimization; that is, a more serious dopamine deficiency required more enzyme targets and lower satisfaction grade. In addition, the therapeutic effects of current clinical medications for PD could be enhanced in combination with new enzyme targets. The increase of toxic metabolites after treatment might be the cause of neurotoxic effects of some current PD medications.


Assuntos
Dopaminérgicos/farmacologia , Distúrbios Distônicos/congênito , Redes e Vias Metabólicas/efeitos dos fármacos , Terminações Pré-Sinápticas/enzimologia , Proteínas Vesiculares de Transporte de Monoamina/deficiência , Algoritmos , Desenho de Fármacos , Cálculos da Dosagem de Medicamento , Distúrbios Distônicos/enzimologia , Lógica Fuzzy , Humanos , Modelos Teóricos , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/enzimologia , Terminações Pré-Sinápticas/efeitos dos fármacos
19.
Metab Brain Dis ; 31(3): 705-9, 2016 06.
Artigo em Inglês | MEDLINE | ID: mdl-26686676

RESUMO

Tyrosine hydroxylase (TH) deficiency is an inborn error of dopamine synthesis. Two clinical phenotypes have been described. The THD "B" phenotype produces a severe encephalopathy of early-onset with sub-optimal L-Dopa response, whereas the "A" phenotype has a better L-Dopa response and outcome. The objective of the study is to describe the expression of key synaptic proteins and neurodevelopmental markers in a fetal brain of THD "B" phenotype. The brain of a 16-week-old miscarried human fetus was dissected in different brain areas and frozen until the analysis. TH gene study revealed the p.R328W/p.T399M mutations, the same mutations that produced a B phenotype in her sister. After protein extraction, western blot analyses were performed to assess protein expression. The results were compared to an age-matched control. We observed a decreased expression in TH and in other dopaminergic proteins, such as VMAT 1 and 2 and dopamine receptors, especially D2DR. GABAergic and glutamatergic proteins such as GABA VT, NMDAR1 and calbindin were also altered. Developmental markers for synapses, axons and dendrites were decreased whereas markers of neuronal volume were preserved. Although this is an isolated case, this brain sample is unique and corresponds to the first reported study of a THD brain. It provides interesting information about the influence of dopamine as a regulator of other neurotransmitter systems, brain development and movement disorders with origin at the embryological state. This study could also contribute to a better understanding of the pathophysiology of THD at early fetal stages.


Assuntos
Encéfalo/metabolismo , Distúrbios Distônicos/congênito , Feto/metabolismo , Mutação , Transtornos Parkinsonianos/genética , Tirosina 3-Mono-Oxigenase/genética , Aborto Espontâneo , Encéfalo/patologia , Dopamina/metabolismo , Distúrbios Distônicos/genética , Distúrbios Distônicos/metabolismo , Distúrbios Distônicos/patologia , Feto/patologia , Humanos , Transtornos Parkinsonianos/metabolismo , Transtornos Parkinsonianos/patologia , Tirosina 3-Mono-Oxigenase/metabolismo , Proteínas Vesiculares de Transporte de Monoamina/genética , Proteínas Vesiculares de Transporte de Monoamina/metabolismo
20.
Orphanet J Rare Dis ; 10: 12, 2015 Feb 08.
Artigo em Inglês | MEDLINE | ID: mdl-25758715

RESUMO

BACKGROUND: Inherited neurotransmitter disorders are primary defects of neurotransmitter metabolism. The main purpose of this retrospective cohort study was to identify prevalence of inherited neurotransmitter disorders. METHODS: This retrospective cohort study does not have inclusion criteria; rather included all patients who underwent cerebrospinal fluid (CSF) homovanillic and 5-hydroxyindol acetic acid measurements. Patients with CSF neurotransmitter investigations suggestive of an inherited neurotransmitter disorder and patients with normal or non-diagnostic CSF neurotransmitter investigations underwent direct sequencing of single gene disorders. RESULTS: There were 154 patients between October 2004 and July 2013. Four patients were excluded due to their diagnosis prior to this study dates. Two major clinical feature categories of patients who underwent lumbar puncture were movement disorders or epilepsy in our institution. Twenty out of the 150 patients (13.3%) were diagnosed with a genetic disorder including inherited neurotransmitter disorders (6 patients) (dihydropteridine reductase, 6-pyruvoyl-tetrahydropterin synthase, guanosine triphosphate cyclohydrolase I, tyrosine hydroxylase, pyridoxine dependent epilepsy due to mutations in the ALDH7A1 gene and pyridoxamine-5-phosphate oxidase deficiencies) and non-neurotransmitter disorders (14 patients). CONCLUSION: Prevalence of inherited neurotransmitter disorders was 4% in our retrospective cohort study. Eight out of the 150 patients (5.3%) had one of the treatable inherited metabolic disorders with favorable short-term neurodevelopmental outcomes, highlighting the importance of an early and specific diagnosis. Whole exome or genome sequencing might shed light to unravel underlying genetic defects of new inherited neurotransmitter disorders in near future.


Assuntos
Distúrbios Distônicos/congênito , Epilepsia/genética , Regulação da Expressão Gênica/fisiologia , Erros Inatos do Metabolismo/genética , Transtornos dos Movimentos/genética , Adolescente , Criança , Pré-Escolar , Estudos de Coortes , Distúrbios Distônicos/diagnóstico , Distúrbios Distônicos/genética , Epilepsia/metabolismo , Humanos , Lactente , Recém-Nascido , Masculino , Erros Inatos do Metabolismo/diagnóstico , Transtornos dos Movimentos/metabolismo , Estudos Retrospectivos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...